Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Journal of neurology, neurosurgery, and psychiatry - 1 Oct 2010

Alves Guido, Brønnick Kolbjørn, Aarsland Dag, Blennow Kaj, Zetterberg Henrik, Ballard Clive, Kurz Martin Wilhelm, Andreasson Ulf, Tysnes Ole-Bjørn, Larsen Jan Petter, Mulugeta Ezra

Abstract excerpt

BACKGROUND: Alzheimer's disease (AD) pathology is found in a considerable portion of patients with Parkinson's disease (PD), particularly those with early dementia (PDD). Altered cerebrospinal fluid (CSF) levels of amyloid-β (Aβ) and tau proteins have been found in PDD, with intermediate changes for Aβ42 in non-demented PD. The authors investigated whether AD-related CSF protein levels are altered and relate to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Apolipoproteins E

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cognition Disorders

Share to Neuropsychological Tests

Share to Norway

Share to Parkinson Disease

Share to Peptide Fragments

Share to tau Proteins

Source

Identifiers

PMID: 20547614
DOI: 10.1136/jnnp.2009.199950

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.PMID 20547614Read ↗

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Semantic proximity Read ↗

Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.Semantic proximity Read ↗

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s diseaseSemantic proximity Read ↗

Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease.Semantic proximity Read ↗

Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.Semantic proximity Read ↗

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.Semantic proximity Read ↗

Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.Semantic proximity Read ↗

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism SyndromesSemantic proximity Read ↗

Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.Semantic proximity Read ↗

APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.Semantic proximity Read ↗

CSF biomarkers in different phenotypes of Parkinson disease.Semantic proximity Read ↗

β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.